Stability of alglucosidase alfa in 0.9% sodium chloride for enzyme replacement therapy in patients with Pompe disease: insights from enzyme activity and cellular uptake measurements

Ina Barzel, Jan-Dietert C Brugma, Edwin H Jacobs, Marianne Hoogeveen-Westerveld, P Hugo M van der Kuy, Tim Preijers

Open source

DOI
10.1136/ejhpharm-2025-004516
Published
2025-08-17
Container
European Journal of Hospital Pharmacy
Publisher
BMJ
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1136/ejhpharm-2025-004516,
  title = {Stability of alglucosidase alfa in 0.9\% sodium chloride for enzyme replacement therapy in patients with Pompe disease: insights from enzyme activity and cellular uptake measurements},
  author = {Ina Barzel and Jan-Dietert C Brugma and Edwin H Jacobs and Marianne Hoogeveen-Westerveld and P Hugo M van der Kuy and Tim Preijers},
  year = {2025},
  journal = {European Journal of Hospital Pharmacy},
  doi = {10.1136/ejhpharm-2025-004516},
  url = {https://doi.org/10.1136/ejhpharm-2025-004516}
}

RIS

TY  - JOUR
TI  - Stability of alglucosidase alfa in 0.9% sodium chloride for enzyme replacement therapy in patients with Pompe disease: insights from enzyme activity and cellular uptake measurements
AU  - Ina Barzel
AU  - Jan-Dietert C Brugma
AU  - Edwin H Jacobs
AU  - Marianne Hoogeveen-Westerveld
AU  - P Hugo M van der Kuy
AU  - Tim Preijers
PY  - 2025
JO  - European Journal of Hospital Pharmacy
DO  - 10.1136/ejhpharm-2025-004516
UR  - https://doi.org/10.1136/ejhpharm-2025-004516
ER  - 

APA

Barzel, I., Brugma, J. C., Jacobs, E. H., Hoogeveen-Westerveld, M., Kuy, P. H. M. V. D., & Preijers, T. (2025). Stability of alglucosidase alfa in 0.9% sodium chloride for enzyme replacement therapy in patients with Pompe disease: insights from enzyme activity and cellular uptake measurements. European Journal of Hospital Pharmacy. https://doi.org/10.1136/ejhpharm-2025-004516

Source records